Crescent Biopharma Inc (CBIO)

Currency in USD
12.500
-0.130(-1.03%)
Closed·
12.5000.000(0.00%)
·
CBIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
12.03512.900
52 wk Range
9.81037.000
Key Statistics
Prev. Close
12.5
Open
12.52
Day's Range
12.035-12.9
52 wk Range
9.81-37
Volume
80.25K
Average Volume (3m)
135.45K
1-Year Change
-50.4362%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CBIO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
28.200
Upside
+125.60%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Crescent Biopharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Crescent Biopharma Inc Company Profile

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.

Compare CBIO to Peers and Sector

Metrics to compare
CBIO
Peers
Sector
Relationship
P/E Ratio
-−3.7x−0.6x
PEG Ratio
-0.070.00
Price/Book
-3.9x2.6x
Price / LTM Sales
-9.6x3.4x
Upside (Analyst Target)
117.4%152.5%41.3%
Fair Value Upside
Unlock−4.8%4.9%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 28.200
(+125.60% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy32.00+156.00%28.00MaintainDec 04, 2025
Stifel
Buy28.00+124.00%28.00MaintainAug 27, 2025
Jefferies
Buy26.00+108.00%-New CoverageAug 25, 2025
H.C. Wainwright
Buy25.00+100.00%-New CoverageAug 11, 2025
Wedbush
Buy27.00+116.00%-New CoverageJul 14, 2025

Earnings

Latest Release
Nov 06, 2025
EPS / Forecast
-1.27 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CBIO Income Statement

People Also Watch

14.060
VOR
-4.81%
3.600
QTTB
0.00%
15.54
PLRZ
+2.91%
0.8502
ATON
-7.27%
2.200
BEAT
-3.93%

FAQ

What Is the Crescent Biopharma (CBIO) Stock Price Today?

The Crescent Biopharma stock price today is 12.500

What Stock Exchange Does Crescent Biopharma Trade On?

Crescent Biopharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Crescent Biopharma?

The stock symbol for Crescent Biopharma is "CBIO."

What Is the Crescent Biopharma Market Cap?

As of today, Crescent Biopharma market cap is 244.37M.

What Is Crescent Biopharma's Earnings Per Share (TTM)?

The Crescent Biopharma EPS (TTM) is -13.45.

From a Technical Analysis Perspective, Is CBIO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Crescent Biopharma Stock Split?

Crescent Biopharma has split 1 times.

How Many Employees Does Crescent Biopharma Have?

Crescent Biopharma has 6 employees.

What is the current trading status of Crescent Biopharma (CBIO)?

As of Jan 16, 2026, Crescent Biopharma (CBIO) is trading at a price of 12.500, with a previous close of 12.500. The stock has fluctuated within a day range of 12.035 to 12.900, while its 52-week range spans from 9.810 to 37.000.

What Is Crescent Biopharma (CBIO) Price Target According to Analysts?

The average 12-month price target for Crescent Biopharma is USD28.2, with a high estimate of USD35 and a low estimate of USD22. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +125.60% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.